Amoxicillin-Clavulanate with Linezolid Combination for Skin and Soft Tissue Infections

Guideline-Based Rationale for This Combination

The World Society of Emergency Surgery recommends combining a beta-lactam with either TMP-SMX or doxycycline for oral therapy when coverage for both streptococci and MRSA is desired, and linezolid is recommended as a first-line oral agent for MRSA coverage (1A recommendation) 1, 2, 3, 4

The combination of amoxicillin-clavulanate and linezolid is indicated for polymicrobial skin and soft tissue infections where both streptococcal species and MRSA are suspected or confirmed 1, 3
This combination can be used for step-down therapy after initial IV treatment when clinical stability is achieved 2, 4

Linezolid offers superior efficacy to vancomycin for MRSA infections (RR 1.09 for clinical cure, RR 1.17 for microbiological cure) 1, 2, 4
Linezolid has excellent tissue penetration into skin and soft tissues 4
Amoxicillin-clavulanate provides streptococcal coverage and anaerobic coverage from the clavulanate component for polymicrobial infections 1, 3, 5

The American College of Clinical Microbiology identifies amoxicillin-clavulanate as a broad-spectrum antibiotic that disrupts normal oral and gastrointestinal flora, increasing thrush risk, and recommends counseling patients about oral candidiasis symptoms and considering prophylactic antifungal therapy in high-risk populations 6
Linezolid is associated with thrombocytopenia (RR 13.06 compared to vancomycin) and nausea (RR 2.45 compared to vancomycin) 5

7 to 14 days of therapy is recommended based on clinical response 1, 2, 4
Oral linezolid has lower daily outpatient costs than IV vancomycin, and the shorter hospital stays associated with linezolid offset its higher per-day inpatient costs 1, 2, 4